Predicting enzyme targets for cancer drugs by profiling human Metabolic reactions in NCI-60 cell lines

BMC Bioinformatics

Volumn 11, Issue , 2010, Pages

  Li, Limin ^a   Zhou, Xiaobo ^b   Ching, Wai Ki ^c   Wang, Ping ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER DRUG; CANCER CELL LINES; CROSS VALIDATION; K-NEAREST NEIGHBORS; METABOLIC NETWORK; METABOLIC REACTIONS; METABOLIC SYSTEMS; TARGET STRUCTURE;

CELL CULTURE; DISEASES; ENZYMES; FORECASTING; GENE EXPRESSION; METABOLISM;

DRUG INTERACTIONS;

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ARTICLE; BIOLOGY; ENZYMOLOGY; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; ENZYME INHIBITORS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 77957556494     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-11-501     Document Type: Article

References (28)

1. Ma H, Goryanin I. Human metabolic network reconstruction and its impact on drug discovery and development. Drug Discovery Today 2008, 13:402-408. 10.1016/j.drudis.2008.02.002, 18468557.
2. Imming P, Sinning C, Meyer A. Opinion - Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006, 5:821-834. 10.1038/nrd2132, 17016423.
3. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?. Nat Rev Drug Discov 2006, 5:993-996. 10.1038/nrd2199, 17139284.
4. Ma HW, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, Goryanin I. The Edinburgh human metabolic network reconstruction and its functional analysis. Mol Syst Biol 2007, 3:8.
5. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 2007, 104:1777-1782. 10.1073/pnas.0610772104, 1794290, 17267599.
6. Kauffman KJ, Prakash P, Edwards JS. Advances in flux balance analysis. Current Opinion in Biotechnology 2003, 14:491-496. 10.1016/j.copbio.2003.08.001, 14580578.
7. Shlomi T, Cabili MN, Herrgard MJ, Palsson BO, Ruppin E. Network-based prediction of human tissue-specific metabolism. Nat Biotech 2008, 26:1003-1010.
8. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008, 24:i232-240. 10.1093/bioinformatics/btn162, 2718640, 18586719.
9. Kutalik Z, Beckmann JS, Bergmann S. A modular approach for integrative analysis of large-scale gene-expression and drug-response data. Nat Biotech 2008, 26:531-539.
10. Nagamine N, Sakakibara Y. Statistical prediction of protein chemical interactions based on chemical structure and mass spectrometry data. Bioinformatics 2007, 23:2004-2012. 10.1093/bioinformatics/btm266, 17510168.
11. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug Target Identification Using Side-Effect Similarity. Science 2008, 321:263-266. 10.1126/science.1158140, 18621671.
12. Almaas E, Oltvai ZN, Barabasi AL. The Activity Reaction Core and Plasticity of Metabolic Networks. PLoS Comput Biol 2005, 1:e68. 10.1371/journal.pcbi.0010068, 1314881, 16362071.
13. Sridhar P, Kahveci T, Ranka S. An iterative algorithm for metabolic network-based drug target identification. Pac Symp Biocomput 2007, 88-99. full_text, 17992747.
14. Sridhar P, Song B, Kahveci T, Ranka S. Mining metabolic networks for optimal drug targets. Pac Symp Biocomput 2008, 291-302.
15. Becker SA, Feist AM, Mo ML, Hannum G, Palsson BO, Herrgard MJ. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox. Nat Protocols 2007, 2:727-738.
16. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007, 1535-7163. MCT-1506-0650.
17. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006, 34:D354-D357. 10.1093/nar/gkj102, 1347464, 16381885.
18. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nat Biotech 2007, 25:1119-1126.
19. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. 3rd International Conference on Systems Biology 2002; Dec 13-15; Stockholm, Sweden 2002, 2498-2504. Cold Spring Harbor Lab Press, Publications Dept.
20. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucl Acids Res 2008, 36:D901-906. 10.1093/nar/gkm958, 2238889, 18048412.
21. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SPC, Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 2001, 46:656-663. 10.1007/s100380170017, 11721885.
22. Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:8822-8826. 10.1073/pnas.91.19.8822, 44698, 7916458.
23. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological Characterization of Multidrug Resistant MRP-transfected Human Tumor Cells. Cancer Res 1994, 54:5902-5910.
24. Salerno M, Garnier-Suillerot A. Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells. European Journal of Pharmacology 2001, 421:1-9. 10.1016/S0014-2999(01)00992-X, 11408043.
25. Bzowska A, Kazimierczuk Z. 2-Chloro-2'-deoxyadenosine (cladribine) and its analogues are good substrates and potent selective inhibitors of Escherichia coli purine-nucleoside phosphorylase. European journal of biochemistry/FEBS 1995, 233:886-890. 10.1111/j.1432-1033.1995.886_3.x, 8521855.
26. de Lemos ML, Hamata L, Jennings S, Leduc T. Interaction between mercaptopurine and milk. Journal of Oncology Pharmacy Practice 2007, 13:237-240. 10.1177/1078155207080802, 18045784.
27. Wong DRP, Derijks LJJPP, den Dulk MOMD, Gemmeke EHKMP, Hooymans PMPP. The Role of Xanthine Oxidase in Thiopurine Metabolism: A Case Report. Therapeutic Drug Monitoring 2007, 29:845-848. 10.1097/FTD.0b013e31815bf4dc, 18043486.
28. Ideker T, Ozier O, Schwikowski B, Siegel AF. Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics 2002, 18:S233-240.